Table 1.
Distribution of the serum anti-HAV antibody concentrations in the samples collected 9 and 11 years after the single-dose vaccination.
| Anti-HAV Concentrations |
Year 9 Cohort, n = 504 | Year 11 Cohort, n = 1335 | ||
|---|---|---|---|---|
| Number of Samples | Detection Rate, % (95% CI) | Number of Samples | Detection Rate, % (95% CI) | |
| 0–9 mIU/mL | 3 | 3/504, 0.6% (0.1–1.8%) |
329 | 329/1335, 24.6% (22.4–27.0%) |
| p * | <0.0001 | |||
| 10–19 mIU/mL | 0 | 0/504, 0% | 48 | 48/1335, 3.6% (2.7–4.7%) |
| p * | <0.0001 | |||
| 20–6000 mIU/mL | 440 | 440/504, 87.3% (84.1–89.9%) |
839 | 839/1335, 62.9% (60.2–65.4%) |
| p * | <0.0001 | |||
| >6000 mIU/mL | 61 | 61/504, 12.1% (9.5–15.3%) |
119 | 119/1335, 8.9% (7.5–10.6%) |
| p * | 0.0432 | |||
* comparing data from the Year 11 Cohort with data from the Year 9 Cohort (Fisher’s exact test).